Alnylam signed a collaboration with Tenaya Therapeutics to access up to 15 novel genetic targets for cardiovascular disease discovery. The deal includes $10 million up front and up to $1.13 billion in milestone payments if targets progress to approved therapeutics. Tenaya will deliver targets and early validation work; Alnylam will lead development and commercialization. The collaboration leverages Tenaya’s locus discovery and gene‑therapy expertise alongside Alnylam’s RNAi and siRNA capabilities, signaling big‑pharma style resource commitments to genetically validated cardiovascular targets. The agreement reflects growing industry interest in genetically informed target portfolios for cardiometabolic indications.